CMC activities in support of the studies and clinical trials included internal formulation development, preclinical and clinical programs, comparator drug, GMP drug product batches, including sunitinib active pharmaceutical ingredient and polymers, and clinical packaging costs
Current Medical Chemistry, 31 (10), 1214-1234
Notably, higher semaglutide dosage (mg) emerged as an independent predictor of these adverse musculoskeletal changes
Harmony Outcomes and SELECT trials only significantly reduced non-fatal MI using abliglutide and semaglutide, respectively [16, 22]
Jhonsi et al., Spectroscopic studies on the interaction of colloidal capped CdS nanoparticles with bovine serum albumin